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Abstract
The use of mesenchymal stromal cell (MSC) transplantation to repair the injured spinal cord has shown consistent benefits in
preclinical models. However, the low survival rate of grafted MSC is one of the most important problems. In the injured spinal
cord, transplanted cells are exposed to hypoxic conditions and exposed to nutritional deficiency caused by poor vascular
supply. Also, the transplanted MSCs face cytotoxic stressors that cause cell death. The aim of this study was to compare
adipose-derived MSCs (AD-MSCs) and bone marrow-derived MSCs (BM-MSCs) isolated from individual C57BL6/J mice in
relation to: (i) cellular characteristics, (ii) tolerance to hypoxia, oxidative stress and serum-free conditions, and (iii) cellular
survival rates after transplantation. AD-MSCs and BM-MSCs exhibited a similar cell surface marker profile, but expressed
different levels of growth factors and cytokines. To research their relative stress tolerance, both types of stromal cells were
incubated at 20.5% O2 or 1.0% O2 for 7 days. Results showed that AD-MSCs were more proliferative with greater culture
viability under these hypoxic conditions than BM-MSCs. The MSCs were also incubated under H2O2-induced oxidative stress
and in serum-free culture medium to induce stress. AD-MSCs were better able to tolerate these stress conditions than BM-
MSCs; similarly when transplanted into the spinal cord injury region in vivo, AD-MSCs demonstrated a higher survival rate
post transplantation Furthermore, this increased AD-MSC survival post transplantation was associated with preservation of
axons and enhanced vascularization, as delineated by increases in anti-gamma isotype of protein kinase C and CD31 immu-
noreactivity, compared with the BM-MSC transplanted group. Hence, our results indicate that AD-MSCs are an attractive
alternative to BM-MSCs for the treatment of severe spinal cord injury. However, it should be noted that the motor function
was equally improved following moderate spinal cord injury in both groups, but with no significant improvement seen
unfortunately following severe spinal cord injury in either group.
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Introduction
Spinal cord injury (SCI) can cause severe neural tissue dam-
age and result in a persistent loss of neurological function.
Recent advances of stem cell-based therapy harbor expecta-
tions for new treatment options for patients with SCI.
Mesenchymal stromal cells (MSCs) isolated from adult tis-
sues have been reported to possess therapeutic activity with
potential applications for SCI treatment. MSC transplanta-
tion into the injured spinal cord promotes axonal regenera-
tion, spares the loss of neurons within the lesion and
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improves motor function1,2,3. We have reported that trans-
plantation of bone marrow-derived MSCs (BM-MSCs) into
an acute SCI model did not differentiate into glial or neuronal
elements, but promoted functional recovery and axonal regen-
eration through production of neurotrophic factors and cyto-
kines with immune regulation function4. In addition to
improvement of motor functions, BM-MSCs also were shown
to regulate neuropathic pain after SCI by neuronal protection
and repair of the destructed blood–spinal cord barrier5.
Although previous studies showed the benefits of BM-
MSC transplants, some problems have been revealed. SCI
can cause various degrees of ischemia6 and oxidative stress7.
These local tissue reactions to damage trigger the immune-
inflammatory cascade and change the cytokine environment
in the injured lesion, which is known as the secondary phase
of the injury response. The stressful microenvironment and
changing cytokine profile causes apoptosis of grafted cells,
so one of the most important unresolved problems of future
stem cell-based therapies for SCI is the enhancement of cell
survival after transplantation. MSCs transplanted into the
injured spinal cord are known to disappear in a few weeks8,9.
We have reported that a combination therapy of BM-MSC
transplants and treatment with anti-interleukin (IL)-6 recep-
tor antibody increased transplanted BM-MSC survival and
motor function recovery through anti-apoptotic activity and
regulation of inflammatory reactions10. However, improve-
ment of survival rates of transplanted MSCs alone, when
they are undergoing severe cell stresses and immune-
biological conditions, as is seen in the acute phase after SCI,
remains a challenging problem.
Adipose-derived MSCs (AD-MSCs) were first isolated
from human subcutaneous fat tissue and have multi-
differentiation potential11. Adipose tissue was recently eval-
uated as an alternative source of cells to bone marrow, which
can be harvested using less invasive methods under local
anesthesia and in larger quantities than in bone marrow12.
Approximately 1 g of adipose tissue yields 5103 MSCs,
which is 500-fold greater than that of bone marrow13. Recent
studies have stated that AD-MSCs have the potential to treat
SCI14–16. However, the therapeutic mechanisms of AD-
MSCs and differences in their activity from BM-MSCs are
still to be clarified.
In this study, we compared AD-MSCs and BM-MSCs to
reveal differences between the cells derived from these tissue
sources; in terms of the cell surface marker presence, mRNA
expression of growth factors and cytokines, and stress toler-
ance in vitro. Furthermore, AD-MSCs and BM-MSCs were
transplanted into a contusion model of SCI to examine MSC
survival rates and promotion of motor function recovery.
Materials and Methods
Isolation and Culture of AD-MSCs and BM-MSCs
AD-MSCs were isolated from 8–10 week-old male C57BL/6
J mice (n¼12, Nippon SLC, Japan) and green fluorescent
protein (GFP)-AD-MSCs were isolated from transgenic
GFP-positive mice of the same age (n¼6; Nippon SLC). The
mice were anesthetized and their subcutaneous adipose tis-
sue was collected and minced using a razor blade. The adi-
pose tissue was then enzymatically dissociated for 50 min at
37C using 0.075% collagenase type I (Sigma-Aldrich, MO,
USA). The solution was passed through a 70 mm filter and
centrifuged at 250g for 5 min. The cells were washed three
times with phosphate-buffered saline (PBS), the pellet was
resuspended and cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen, Carlsbad, CA, USA) supple-
mented with 10% fetal bovine serum (FBS; Invitrogen).
Cultures were maintained at 80–90% confluent levels in a
37.5C incubator with 5% CO2 and passaged with 0.025%
trypsin/ethylenediaminetetraacetic acid (Invitrogen) when
required.11 BM-MSCs were also isolated from 8–10 week-
old male C57BL/6 J mice or CAG-EGFP mice and main-
tained under the same conditions as AD-MSCs. The mice
were anesthetized and their limbs were amputated followed
by removal of skin, muscle and as much connective tissue as
possible. The mice were euthanized by CO2 after harvesting
of adipose tissue and bone marrow. Bone marrow was har-
vested from the femur and tibia with 25-gauge needles and
passed through a 70 mm filter and centrifuged at 250g for 5
minutes. The cells were washed with PBS three times and
cultured in the same culture medium as AD-MSCs (DMEM
with 10% FBS), undergoing routine passaging through tryp-
sinization at 80–90% confluence.
Flow Cytometry
To analyze the expression of specific cell surface proteins on
AD-MSCs and BM-MSCs, flow cytometric analysis was
performed (n¼5 AD-MSCs and n¼5 BM-MSCs). The cells
from the third passage were trypsinized into single-cell sus-
pensions and labeled with the following anti-mouse antibo-
dies conjugated to fluorochromes: PerCP-Cy5.5-CD11b
(0.25 mg/100 ml; BD Biosciences, Bedford, MA, USA),
PE-CD14 (0.25 mg/100 ml; BioLegend, CA, USA), PE-
CD34 (0.25 mg/100 ml; BioLegend), PE-CD44 (10 ml/100
ml; BioLegend), APC-CD45 (0.25 mg/100 ml; BioLegend),
PE-CD49d (0.25 mg/100 ml; BioLegend), PE-CD73 (0.25 mg/
100 ml; BioLegend), PE-CD90.2 (0.25 mg/100 ml; BioLe-
gend), PE-CD105 (0.25 mg/100 ml; Abcam, Cambridge,
UK), PE-CD106 (0.25 mg/100 ml; BioLegend), APC-
CD133 (0.25 mg/100 ml; BioLegend) and PE-Sca-1 (0.5
mg/100 ml; BioLegend). Cells were incubated on ice for 45
minutes with each antibody. Corresponding mouse isotype
antibodies were used as controls (1:5; Santa Cruz Biotech-
nology, TX, USA). The cells were analyzed using the
fluorescence-activated cell sorting instrument (FACSCanto
II; BD Biosciences) according to the manufacture’s protocol.
The percentage of expressed antigen was calculated for
10,000 gated-cell events and the data processed (FACSDiva
software; BD Biosciences).
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Comparison Analysis of mRNA Expression of AD-MSC
and BM-MSC
For assessment of in vitro mRNA expression of AD-MSCs
and BM-MSCs, the QuantiGene Plex 2.0 Reagent System
(Affymetrix, CA, USA) was used. This system is a sandwich
nucleic acid hybridization method that uses branched DNA
technology to directly quantify nucleic acid molecules at
physiological levels17. Total RNA was isolated from
1105 stem cells. AD-MSCs and BM-MSCs (n¼3; both
passage 3) were cultured in DMEM with 10% FBS in a
T25 flask for 24 hours in a 37.5C incubator with 5%
CO2, and mRNA was isolated and purified according to the
protocol of the manufacture. The mRNA expression was
determined using the sets of bead-based oligonucleotide
probe specific for mouse cytokines developed by Panomics
Inc. (CA, USA), these included; chemokine ligand (CCL)2,
CCL5, chemokine (C-X-C motif) ligand (CXCL)10,
CXCL12, basic fibroblast growth factor (b-FGF), vascular
endothelial growth factor A (VEGF-A), hepatocyte growth
factor (HGF), insulin-like growth factor 1 (IGF-1), platelet-
derived growth factor b (PDGF-b), brain-derived neuro-
trophic factor (BDNF), nerve growth factor, and angiopoietin
1 (Ang-1). Samples were analyzed using a Bio-Plex System
Array reader with Luminex 100xMAP technology, and data
were acquired using Bio-Plex Data Manager software version
5.0 (Bio-Rad Laboratories, CA, USA). Assays were per-
formed according to the manufacturer’s protocol (Panomics
Inc.). mRNA expression was normalized to the Hprt house-
keeping gene, which was not significantly different between
treatment groups.
Cell Culture under Different Oxygen Conditions
For assessment of cell proliferation under the hypoxic con-
dition, AD-MSCs and BM-MSCs (n¼3; both passage 3)
were seeded into six-well plates at the density of 1104 cells
per well and cultured in DMEM with 10% FBS under the
20.5% O2 and 1.0% O2 conditions for 7 days. The culture
medium was changed 1, 3, and 5 days after seeding. The
cells were trypsinized and stained with 0.4% trypan blue and
counted using a cell counter (Countess Automated Cell
Counter; Invitrogen) at days 1, 3, 5, and 7 after seeding.
Quantification of Cell Viability Under Oxidative Stress
To investigate cellular viability and metabolic activity, the
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylami-
no)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and
calcein/EthD staining were performed. The XTT assay is
based on the same principle as the 3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay, but
has higher sensitivity and a higher dynamic range18. AD-
MSCs and BM-MSCs (n¼3; both passage 3) were seeded
into 96-well plates at a density of 3103 cells per well and
cultured for 24 hours in DMEM with 10% FBS in a 37.5C
incubator with 5% CO2 to permit all cells to attach, and then
the culture medium was replaced with DMEM with 10%
FBS containing 0, 250, 500, 750, and 1000 mM of H2O2 (six
replicate wells for the AD-MSCs or BM-MSCs tested) or
with serum-free DMEM only (no H2O2 treatment), and incu-
bated for a further 24 hours. After this the wells were washed
twice with PBS, and 50 ml of the 0.5mg/ml XTT dye mixture
(Cell Proliferation Kit II; Sigma-Aldrich) was added into
each well. The plate was incubated in the XTT dye for 5
hours after which absorbance at 475 nm was measured by a
UV-visible spectrophotometer microplate reader
(VersaMax®; Molecular Devices, CA, USA). Cell viability
was also investigated using calcein AM/EthD-1 staining kit
(LIVE/DEAD® Viability/Cytotoxicity reagent; Invitrogen).
This assay is a mixture of calcein AM and ethidium
homodimer-1 (EthD-1). Calcein AM is a membrane-
permeable dye that is used for labeling of living cells with
impermeant green-wavelength fluorophore. Ethidium
homodimer-1 does not permeate live cells, but it can
enter into dead cells that have a porous membrane and
bind to nucleotide to produce red fluorescence19. AD-
MSCs and BM-MSCs were exposed to H2O2 or serum-
free conditions for 24 hours, as described above, then the
medium was removed and replaced with PBS containing
5 mM ethidium homodimer (EthD-1) and 5 mM calcein
AM (LIVE/DEAD staining). After that cells were incu-
bated at 37C for 40 minutes and the number of living
(green) or dead (red) cells were counted manually by
inverted fluorescence microscopy, where cells were
counted in 10 randomly selected microscopic fields (orig-
inal magnification 200) in each well.
Animal Model of SCI
Adult C57BL/6 J male mice 8–10 weeks old (n¼128) and
adult Thy1-YFP transgenic mice (https://www.jax.org/
strain/003709) 8–10 weeks old (n¼30) were used to examine
the survival and effects of transplanted AD-MSCs and BM-
MSCs. Thy-1 protein appears in the cell body, dendrites and
in the axons at the terminal phase of axonal growth20,21.
Hence, Thy1-YFP transgenic mice, which is the parent line
backcrossed to C57BL/6 J, have been used as a means of
tracing neuronal axonal growth in several studies22,23. The
animals were anesthetized with an isoflurane (Forane®;
Abbot Japan, Osaka, Japan) and oxygen mixture (2.5% for
induction and 1.5% for maintenance) and underwent T9-T10
total laminectomy under magnification using microscope. A
contusion SCI was produced using a commercially available
SCI device (Infinite Horizons Impactor; Precision Systems
& Instrumentation LLC, VA, USA) with an impact force of
60-kdyne (moderate contusion; n¼80) or 80-kdyne (severe
contusion; n¼68, as previously described24,25,26. The mice
received manual bladder expression twice daily until recov-
ery of spontaneous sphincter control and voiding. They were
then transferred to a bacteria-free biologically clean room set
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on a 12-hour light/dark cycle and provided with food and
water ad libitum.
Animals and Experimental Groups
At 3 days after the injury, the animals were divided into eight
sets of experimental conditions as follows:
i. moderate contusion model treated with AD-MSC
(Mo-AD-MSC group; 1105 cells/3 ml PBS;
C57BL/6 J mice; n¼20, Thy1-YFP transgenic
mice; n¼10)
ii. moderate contusion model treated with BM-MSCs
(Mo-BM-MSC group; 1105 cells/3 ml PBS;
C57BL/6 J mice; n¼20, Thy1-YFP transgenic
mice; n¼10)
iii. control group of moderate contusion with 3 ml PBS
without cells (Mo-control group; C57BL/6 J mice;
n¼20, Thy1-YFP transgenic mice; n¼10).
iv. severe contusion model treated with AD-MSCs
(Se-AD-MSC group; 1105 cells/3 ml PBS;
C57BL/6 J mice; n¼10)
v. severe contusion treated with BM-MSCs (Se-BM-
MSC group; 1105 cells/3 ml PBS; C57BL/6 L;
n¼10)
vi. control group of severe contusion model with 3 ml
PBS without cells (Se-control group; C57BL/6 J
mice; n¼10).
vii. severe contusion model treated with GFP-AD-
MSCs (Se-GFP-AD-MSC group; 1105 cells/3
ml PBS; C57BL/6 J mice; n¼19)
viii. severe contusion model treated with GFP-BM-
MSCs (Se-GFP-BM-MSC group; 1105 cells/3
ml PBS; C57BL/6 J mice; n¼19)
We previously reported that the appropriate transplanta-
tion time for MSCs to survive in the injured spinal cord was
3 days after injury13. In this study, based on our previous
publication, all groups underwent the second surgery for
MSC transplantation 3 days after contusion. MSCs (AD-
MSCs, BM-MSCs, GFP-positive AD-MSCs, GFP-positive
BM-MSCs) in 3 ml PBS were injected into the injury epicen-
ter, which was clearly seen in the central region of the lami-
nectomy area. Control groups were injected with 3 ml PBS
without cells. In all groups, the MSC or PBS were injected
into the contusion epicenter using a 10-ml Hamilton syringe
with a 32-gauge stainless steel needle attached to an auto-
mated micropump. The needle remained in place for 5 min-
utes after injection to ensure that all cells were administered
into the spinal cord. After surgery, the mice were maintained
in an isothermic cage until recovery.
Assessment of Transplanted Cell Survival
The severe SCI model was used to evaluate the survival rate
of transplanted AD-MSCs or BM-MSCs in vivo. The Se-
GFP-AD-MSC group and Se-GFP-BM-MSC group animals
were examined at 7, 14, 21, and 28 days (1–4 weeks) after
transplantation. The GFP-positive cells were considered
most likely to be surviving MSCs because, as we have shown
previously, they did not differentiate into glial or neuronal
elements27 and GFP-positive cells disappear if these are
taken up by phagocytic cells. Under anesthesia, mice were
intracardially perfused with ice-cold PBS, followed by
fixation with 4% paraformaldehyde in PBS. Excised tissue
samples were immersed in sucrose for 24 hours, and seg-
ments of the spinal cord (T8 to T12) were cut on a cryostat
into sagittal frozen sections at 14 mm thick. To count the
number of GFP-positive cells present in tissue sections,
three midsagittal sections of the injured portion of har-
vested spinal cords removed from each of four mice in each
group were randomly selected and 20 high-magnification
(200) non-overlapping photomicrographs of the injury
epicenter were collected using a confocal microscope (TCS
SP2; Leica Microsystems, Wetzlar, Germany); these
digitized images were then used to count the number of
GFP-positive cells using a color image analyzer software
(MacSCOPE; Mitani, Japan)10.
Immunohistochemistry and Semi-Quantitative Analysis
of Tissue Staining
Once deep anesthesia was achieved, the Mo-AD-MSC
group, Mo-BM-MSC group, Mo-control group, Se-GFP-
AD-MSC group, and Se-GFP-BM-MSC group of mice were
intracardially perfused with 200 ml of ice-cold PBS, fol-
lowed by fixation with 4% paraformaldehyde in PBS, and
the spinal cords were excised and post-fixed with 4% paraf-
ormaldehyde for 3 hours. Then, the samples were immersed
in 10% sucrose in PBS at 4C for 24 hours, and 30% sucrose
in PBS for next 24 hours. The spinal cord segments (T8 to
T12) were prepared for sectioning using optimum cutting
temperature compound (Sakura Finetek, Japan) and frozen
at 80C and cut using a cryostat into the axial or sagittal
sections at 14 mm thick. The sections were rinsed in PBS
three times after fixing with 4% paraformaldehyde in PBS.
For immunofluorescence staining with fluorescent antibo-
dies, frozen sections were permeabilized with 0.1 mol/l
Tris-HCl buffer (pH 7.6) containing 0.3% Triton X-100
(Sigma-Aldrich). The following primary antibodies were
diluted in commercial diluent (Antibody Diluent with Back-
ground Reducing Components; Dako Cytomation, Glostrup,
Denmark) and applied overnight at 4C: anti-gamma isotype
of protein kinase C (PKCg; 1:50, rabbit immunoglobulin
(Ig)G; Cell Signaling Technology, Inc., MA, USA); anti-
pAkt monoclonal antibody (1:100, rabbit IgG; Cell Signal-
ing Technology, Inc.); anti-extracellular signal-regulated
protein kinase 1/2 (ERK1/2) monoclonal antibody (1:200,
rabbit IgG; Cell Signaling Technology, Inc.); anti-CD31
monoclonal antibody (1:250, rabbit IgG; Abcam). The sec-
tions were then incubated for 1 hour at room temperature
with Alexa fluor-conjugated 488 or 568 secondary antibo-
dies (1:250; Molecular Probes, OR, USA). Then the sections
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were rinsed in PBS three times and examined by epifluores-
cence. Control immunolocalization using the same immuno-
histochemical methods minus the primary antibodies was
performed and this demonstrated an absence of signal. The
digitized images of immunofluorescence were collected
using a confocal laser scanning microscope (TCS SP2; Leica
Microsystems). This time-point was used to evaluate blood
vessels (by CD31 immunopositivity) because previous
research had shown that angiogenesis both diminished cystic
cavity formation at 3–7 days after SCI and that neuronal
fiber outgrowth was associated with new blood vessels28.
In the spinal cord, PKCg is an intracellular signaling kinase
found in the axons of the corticospinal tract29.
For semi-quantitative analysis of the presence of PKCg-
positive MSCs at 2 and 4 weeks after transplantation in
animals used in the moderate contusion model, the following
procedure was performed; five axial sections of length
+500 mm from the epicenter were selected randomly, and
high-magnification (200) photomicrographs of the poster-
ior funiculus were taken (TCS SP2; Leica Microsystems),
then analyzed using color image analyzer software (Mac-
SCOPE; Mitani). To evaluate the survival response of trans-
planted MSCs, we assessed by immunopositivity the
presence of the prosurvival pAkt and ERK1/2 signaling
pathways specifically within these transplanted cells (GFP-
labeled), and not in other cells within the spinal cord. The
Akt pathway is a signal transduction pathway that promotes
cellular survival and growth in response to extracellular sig-
nals. Also, ERK1/2 is an important subfamily of mitogen-
activated protein kinases that control cellular activities. We
reported that MR-16 treatment, which blockades IL-6 signal-
ing, increased the expression Akt and ERK1/2 in trans-
planted MSCs, with levels of expression strongest at 7
days after transplantation10. To semi-quantify the expression
of Akt and ERK1/2, the following procedure was performed
using the severe contusion model: three mid-sagittal sections
at the injury epicenter were selected at random, and 10 non-
overlapping high-magnification photomicrographs (400)
were taken per section (TCS SP2; Leica Microsystems). The
numbers of Akt/ERK1/2 positive cells that colocalized with
GFP positivity were counted using color image analyzer
software (MacSCOPE: Mitani).
Assessment of Motor Function
Behavioral outcome after transplantation of MSCs was eval-
uated by the Basso Mouse Scale (BMS) for locomotion, in
which the scores range from 0 points (no ankle movement) to
9 points (complete functional recovery). BMS scores of each
group (n¼10 animals per group) were recorded at 7, 14, 21,
28, 35, and 42 days (for 6 weeks) after treatment by two
independent examiners blinded to the experimental condi-
tions (HN and SW); the groups tested were the Mo-AD-MSC
group, Mo-BM-MSC group, Mo-control group, Se-AD-
MSC group, Se-BM-MSC group, and Se-control group.
When the scores of the right and left hind limbs were
different from each other, the average of the two scores were
recorded.
Statistical Analysis
All experiments and analysis were performed on at least
three animals per group. Data have been reported as means
+ standard deviation (SD). Differences between groups
were examined for statistical significance using either the
paired Student’s t test or one-way analysis of variance. A
p<0.05 denoted the presence of significant difference with
Tukey’s post-hoc analysis. All statistical analyses were per-
formed using SPSS 10.0 (SPSS Inc., Chicago, USA).
Results
Cell Surface Markers of AD-MSCs and BM-MSCs
The results of flow cytometric analysis of cell surface mar-
kers are shown in Table 1. Flow cytometric analysis demon-
strated that AD-MSCs and BM-MSCs were shown to have
the same surface maker pattern; positive for CD34
(86.3%+18.0%; 98.2%+2.3%), CD44 (95.0%+6.8%;
99.9%+0.1%), CD73 (47.1%+6.9%; 56.4%+16.1%),
CD90.2 (46.5%+1.8%; 56.6%+12.7%)), CD106
(95.3%+2.8%; 88.2%+4.6%) and Sca-1 (97.6%+3.3%;
96.1%+5.2%), but not CD11b (0.8%+0.4%; 0.4%+0.2%),
CD14 (0.7%+0.6%; 4.3%+1.0%), CD45 (0.6%+0.6%;
1.7%+0.9%), CD49d (1.1%+1.3%; 0.8%+0.3%) CD105
(5.4%+6.2%; 1.3%+1.3%) and CD133 (0.6%+0.5%;
0.5%+0.4%).
Comparison Analysis of mRNA Expression of AD-MSCs
and BM-MSCs
The QuantiGene Plex 2.0 Reagent System (Affymetrix) was
used for comparative analysis of cytokine synthesis. The
relative mRNA expression of AD-MSCs and BM-MSCs are
shown in Fig. 1. Many of the cytokines examined were
expressed at similar levels in both cell types; however, there
were significant differences in the relative expression of
CCL2, CXCL12, PDGF-b, and VEGF-A, with AD-MSCs
dominant for each cytokine, and BDNF with BM-MSCs
dominant. The data indicated that both MSCs have potential
to synthesize cytokine/chemokine, but that they differ from
each other.
Cell Proliferation Ability Under Different
Oxygen Conditions
The growth kinetics of AD-MSCs and BM-MSCs were
analyzed to determine which cell type was more tolerant
to hypoxia. As shown in Fig. 2A, AD-MSCs and BM-MSCs
could be culture expanded even under 1.0% O2 conditions
by day 5. However, AD-MSCs were more proliferative in
1.0% O2 conditions compared with their growth in 20.5%
O2 conditions, whereas the number of BM-MSCs under
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1.0% O2 conditions was decreased. There were significant
differences in cell numbers recorded at day 5 and 7, for
each cell type, suggesting that in the later stages of culture
AD-MSCs maintained their proliferation rates in hypoxia,
while BM-MSCs decreased their proliferation ability under
hypoxia.
Metabolic Activity and Cell Viability Under
Oxidative Stress
Oxidative stress or serum-free conditions are known to
induce apoptosis in various cells. For quantification of meta-
bolic activity and viability of AD-MSCs and BM-MSCs
under stress, calcein AM/EthD staining and XTT assays
were performed. After exposure to high H2O2 concentrations
and serum-free medium, the numbers of calcein AM-
positive (viable) BM-MSCs were markedly decreased.
AD-MSCs were also damaged following exposure to
oxidative stress or serum-free medium, but in contrast to
BM-MSCs, AD-MSCs were more tolerant to these stress
exposures as demonstrated by greater numbers of viable
cells (Fig. 2B–D). XTT assays showed reduction of meta-
bolic activation under high H2O2 concentrations, however,
increased relative absorbance of AD-MSCs compared with
BM-MSCs in the 500, 750, 1000 mM H2O2 and serum-free
medium (Fig. 2E).
Transplanted MSC Viability Detected by GFP-labeling
and Akt/ERK 1/2 Positivity
In the severely injured spinal cord, the number of GFP-
positive cells gradually decreased in both groups with time.
By 4 weeks after GFP-BM-MSC transplantation, very few
viable cells were observed; however, in the GFP-AD-MSC
group the area of GFP positivity with cell protrusions evi-
dent, indicative of a stromal morphology30, remained
strongly apparent throughout the time period and was signif-
icantly higher than that of the GFP-BM-MSC group at 2, 3, 4
weeks after transplantation (Fig. 3).
Previously, we found that the prosurvival signaling fac-
tors, Akt and ERK 1/2, are mostly upregulated in trans-
planted MSCs at 7 days after transplantation31. Based on
this result, we performed immunofluorescent staining to
compare the expression of Akt and ERK 1/2 at 7 days after
AD-MSC and BM-MSC transplantation. As shown in Fig. 4,
most of the AD-MSCs that were present at this time
expressed Akt and relatively stronger GFP (with cell protru-
sions evident) even in the severe contusion model. In con-
trast, the appearance of GFP in BM-MSCs was weaker than
the AD-MSCs and there were few Akt positive BM-MSCs
apparent. Similarly, there was a significant increase in the
prevalence of ERK 1/2 immunopositive GFP-AD-MSCs
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Immunohistochemistry for Corticospinal Tract Axons
and Endothelial Cells
To compare the therapeutic effects of AD-MSCs and BM-
MSCs on spinal cord repair, immunofluorescence staining of
PKC-positive corticospinal tract axons (YFP transgenic
mice) and CD31-positive vascular endothelium was per-
formed in the moderate contusion model. It has already been
demonstrated that BM-MSC transplantation promotes axo-
nal regeneration, so here we compared the AD-MSC group
and BM-MSC group. Staining for PKCg levels showed that
the area of spared corticospinal tracts in the AD-MSC trans-
planted group was significantly greater than the BM-MSC
transplanted group and control group at 2, 4 and 6 weeks post
transplantation (Fig. 5A, B). In addition, a significantly
greater CD31-positive area was seen in the AD-MSC group
compared with the BM-MSC group and the control group at
1 and 2 weeks post transplantation (Fig. 5C, D).
Changes in Locomotor Function
The motor function was assessed for 6 weeks after AD-MSC
and BM-MSC transplantation versus control groups. Motor
function scores were increased compared with the Mo-
control group in both the Mo-AD-MSC group and Mo-
BM-MSC group (i.e., in the moderate contusion model),
with a significantly improved BMS score in both MSC trans-
planted groups versus control, but no significant difference
between the MSC groups (Fig. 6A). However, there were no
significant changes over time or between groups in the Se-
AD-MSC, Se-BM-MSC and Se-control groups (i.e. in the
severe contusion model; Fig. 6B).
Discussion
MSC transplantation is a promising therapy for the repair of the
damaged nervous system32. We have demonstrated that MSC
transplantation regulates inflammatory and immune responses
and promotes functional improvement after SCI27,10. Bone
marrow is a commonly used source for MSCs, however,
BM-MSC transplantation has encountered difficulty including
poor cell survival after transplantation. Adipose tissue contains
larger numbers of MSCs than bone marrow and is more acces-
sible with less donor site morbidity following harvest12. Hence,
the use of AD-MSCs represents an attractive alternative to BM-
MSCs. The major findings of our current research were: (1) the
surface marker expression of AD-MSCs and BM-MSCs iso-
lated from individual C57BL6/J mice was similar; (2) AD-
MSCs showed higher tolerance to cytotoxic factors such as
hypoxia, serum deprivation, and oxidative stress than
BM-MSCs; (3) AD-MSCs expressed growth factors and cyto-
kines/chemokines with some similarity and some differences
when compared with BM-MSCs; (4) the survival rate of AD-
MSCs was higher than BM-MSCs after transplantation into a
severe SCI model in vivo; (5) AD-MSC transplantation con-
tributed to greater levels of neuronal/vascular protection com-
pared with BM-MSCs and control groups; (6) the motor
function was equally improved in both AD-MSCs and BM-
MSCs compared with the control group following moderate
SCI, but there was no significant improvement following
severe SCI in either of the treated groups.
Some investigators have reported that the surface
immunophenotype of AD-MSCs resembles that of BM-
MSCs33,34,35,16. On the other hand, differences in surface
markers expression also have been reported between AD-
Fig. 1. Comparative analysis of mRNA expression of AD-MSCs and BM-MSCs using the QuantiGene Plex 2.0 Reagent System. The data
showed that the expression of CCL2, CXCL12, PDGF-b, and VEGF-A in AD-MSCs were significantly higher than their expression in BM-
MSCs. In contrast, BM-MSCs expressed significantly higher levels of BDNF than AD-MSCs. Data are shown as mean+SD. n¼3 per groups,
*p<0.05.
AD-MSC: adipose-derived mesenchymal stromal cell; BDNF: brain-derived neurotrophic factor; BM-MSC: bone marrow-derived mesench-
ymal stromal cell; CXCL12: chemokine (C-X-C motif) ligand 12; PDGF-b: platelet-derived growth factor b; SD: standard deviation
VEGF: vascular endothelial growth factor.
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MSCs and BM-MSCs. For example, CD34 is present on
human AD-MSCs early in passage, but has not been found
on human BM-MSCs36,37,11, and CD34 expression decreases
over time in culture38. The CD markers of murine MSCs are
still not be clarified. Pester et al. investigated the character of
MSCs isolated from five strains of mice bone marrow and
they reported that CD markers varied in the expression of
CD3436. Our results showed that AD-MSCs and BM-MSCs
isolated from the same C57BL/6 J mice express a similar
pattern of CD markers and that the surface markers, includ-
ing CD34, may not be a useful marker to distinguish between
AD-MSCs and BM-MSCs.
Current thinking is that the potential beneficial effects of
MSCs in SCI are not related to neuronal or glial differentia-
tion of MSCs, but rather from their secretion of growth
factors and/or cytokines. Recent research showed that AD-
MSCs and BM-MSCs synthesize many cytokines and
growth factors39,40, which may regulate their regenerative
activity after transplantation. Wright et al. reported that MSC
transplantation may promote axonal regeneration both by
stimulating nerve growth via secreted factors and also by
reducing the nerve-inhibitory effects of the extracellular
molecules present20. In this in vitro study, MSCs acted as
“cellular bridges” and also “towed” neurites over nerve-
Fig. 2. Assessment of stress tolerance of AD-MSCs and BM-MSCs under hypoxia and oxidative stress. (A) The proliferation rates of AD-
MSCs and BM-MSCs under 20.5% O2 or 1.0% O2 culture conditions. At day 5, the number of AD-MSCs in 1.0% was significantly greater than
AD-MSCs in 20.5% O2. In contrast, the BM-MSC proliferation rate in 1.0% O2 was significantly decreased at day 7. Data are shown as
mean+SD, n¼3 per groups, *p<0.05. (B) Representative images of AD-MSCs and BM-MSCs following 24 hours incubation in H2O2
containing DMEM/10% FBS medium or serum-free medium, stained with calcein AM/EthD-1 (LIVE/DEAD). Cells were photographed using
a fluorescence microscope at 100 magnification. Living cells (green) were stained with calcein AM, and dead cells (red) were stained with
EthD-1. (C, D) The number of the living/dead cells incubated in H2O2 at different concentrations or in serum-free medium. There were
significantly greater numbers of viable AD-MSCs than BM-MSCs at the higher concentrations (750 mM, 1000 mM) of H2O2 and in serum-free
conditions. Data are shown as mean+SD. n¼6 wells per groups, *p<0.05. (E) Cell viability was further assessed using the XTT assay to test
for metabolic activity. As shown, metabolic activity in AD-MSCs exposed to high concentrations of H2O2 (500–1000 mM) and in serum-free
medium was significantly greater than that of BM-MSCs under the same stress condition. Data are shown as mean+SD. n¼6 wells per
groups, *p<0.05.
AD-MSC: adipose-derived mesenchymal stromal cell; BM-MSC: bone marrow-derived mesenchymal stromal cell; DMEM: Dulbecco’s
modified Eagle’s medium; FBS: fetal bovine serum; XTT: 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-
tetrazolium hydroxide.
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inhibitory substrates. Hence, the morphology of surviving
transplanted MSCs, which demonstrated a stromal morphol-
ogy with cell protrusions, indicated possible similar modes
of activity30. Therefore, we performed multiplex bead assays
to identify and compare cytokines secreted by murine AD-
MSCs and BM-MSCs isolated from the same mice. This
technique does not require target gene amplification thereby
reducing measurement bias. Our data showed that AD-MSCs
express and may synthesize higher levels of CXCL12,
PDGF-b, and VEGF-A than BM-MSCs in vitro. VEGF is
Fig. 3. The survival of AD-MSCs and BM-MSCs after transplantation into the injured spinal cord. (A) Representative images are shown of
midsagittal spinal cord sections in mice transplanted with GFP-labeled AD-MSCs and GFP-labeled BM-MSCs in the severe SCI model. High-
magnification pictures were taken from respective boxed area showing GFP-MSCs with cell protrusions. Scale bars: 200 mm, 20 mm. (B) The
midsagittal GFP-positive area was analyzed after transplantation. There was a significantly higher number of positive cells of GFP-labeled AD-
MSCs than GFP-labeled BM-MSCs at 2, 3, and 4 weeks after transplantation. Data shown as means+SD. n¼4 per groups, *p<0.05.
AD-MSC: adipose-derived mesenchymal stromal cell; BM-MSC: bone marrow-derived mesenchymal stromal cell; GFP: green fluorescent
protein; SCI: spinal cord injury; SD: standard deviation.
Fig. 4. Akt and ERK 1/2 immunoreactivity in transplanted AD-MSCs and BM-MSCs. (A) Representative immunofluorescence images show
the colocalization of Akt and ERK1/2 (red) GFP-positive MSC (green) with cell protrusions in the spinal cord epicenter on 7 days after
transplantation. Scale bars: 20 mm. (B) The number of Akt or ERK1/2 and GFP-positive MSCs. The amount of GFP-AD-MSC colocalization
with Akt or ERK1/2 was significantly increased compared with that of GFP-BM-MSCs. Data are shown as mean+SD. n¼3 per groups,
*p<0.05.
AD-MSC: adipose-derived mesenchymal stromal cell; BM-MSC: bone marrow-derived mesenchymal stromal cell; GFP: green fluorescent
protein; MSC: mesenchymal stromal cell.
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a one of the major factors of neovascularization41 and AD-
MSCs synthesize increased VEGF in hypoxic conditions42.
Moreover, VEGF treatment has neuroprotective effects in
SCI and improves motor function43,44. Our data showed that
VEGF-A expression was greater in AD-MSCs than BM-
MSCs even when cultured at 20.5% O2. CXCL12 is
expressed in the dorsal corticospinal tract and meningeal
cells of the spinal cord during development45. Along with
its receptor CXCR4, CXCL12 is a key wound healing factor
that promotes axonal outgrowth46, hematopoiesis47, angio-
genesis48, and has anti-apoptotic effects48. Liu et al. reported
that the CXCL12 pretreated MSC demonstrated increased
cell survival and proliferation in vitro. They also showed
CXCL12 pretreatment inhibited apoptosis induced by
H2O2 and increased the secretion of prosurvival and
angiogenic cytokines49. In this study, we found that
CXCL12 was expressed to a greater level in AD-MSCs than
BM-MSCs. Furthermore, we found increased preservation of
the corticospinal tract and vascular endothelium after AD-
MSC transplantation compared with BM-MSCs. The trophic
factors secreted by AD-MSCs might contribute to these ther-
apeutic effects.
Damage to the spinal cord is thought to be composed of
two phases. The first phase of SCI is the initial physical
insult to the spinal cord leading directly to cell death and
bleeding. The secondary phase consists of multiple patho-
physiological processes that cause further tissue loss and
dysfunction. Several secondary mechanisms are including
hypoxia6, acidosis50, and free radical formation7,31. Trans-
planted MSCs are exposed not only to cytotoxic conditions
Fig. 5. The effects of AD-MSC and BM-MSC transplantation on corticospinal tracts and blood vessel formation in severe SCI. (A)
Representative images are shown for each experimental group of the corticospinal tracts + 500 mm from the injury epicenter at 4 weeks
after transplantation. Scale bar: 50 mm. (B) Immunofluorescence positive area of PKCg (red) merged with axons in YFP-mice at 2, 4, and 6
weeks after AD-MSC and BM-MSC transplantation versus controls (no cells). Data showed that the PKCg-positive corticospinal tracts were
significantly increased at 2, 4, and 6 weeks after transplantation in the AD-MSC transplanted group compared with the BM-MSC transplanted
group and control group. (C) Representative images showing CD31 immunofluorescence staining (red) at 1 and 2 weeks after transplanta-
tion of AD-MSCs or BM-MSCs versus controls (no cells). CD31 positive blood vessels area and tube formation were increased in the AD-
MSC transplanted group. Scale bar: 50 mm). (D) Immunofluorescence positive area of CD31 on 1 and 2 weeks after transplantation. Note
the CD31 positive capillary density was significantly increased in AD-MSC transplanted group compared with the BM-MSC transplanted
group and control group. Data are shown as mean+SD. n¼5 per groups, *p<0.05.
AD-MSC: adipose-derived mesenchymal stromal cell; BM-MSC: bone marrow-derived mesenchymal stromal cell; PKCg: anti-gamma isotype
of protein kinase C; SCI: spinal cord injury; SD: standard deviation.
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due to tissue damage, but to a lack of oxygen and nutrients
caused by poor vascular supply. Recent studies indicate that
AD-MSCs may have increased stress tolerance to hypoxia
and lower nutrition levels compared with BM-MSCs. In
generally, living cells need oxygen to survive, but the level
of oxygen may affect cell viability and proliferation. Yama-
moto et al. reported that hypoxia enhanced the proliferation
rate of AD-MSCs51. They showed that the expression of
Oct3/4 and Nanog, as a stem cell marker, and the secreted
growth factors were increased under the hypoxic condition.
Oh et al. reported that neural stem cells co-transplanted with
AD-MSCs showed better survival rates than neural stem
cells transplanted alone52. Moreover, hypoxic stress also sti-
mulates AD-MSC production of angiogenic cytokines such
as VEGF53,41. In another study, AD-MSCs proliferated bet-
ter in culture medium containing low (2%) levels of serum
than BM-MSCs, and secreted higher levels of HGF and
VEGF when cultured in low serum compared with high
(20%) serum medium34. Therefore, we hypothesized that
AD-MSCs have a higher tolerance to hypoxia, oxidative
stress, and serum-free conditions than BM-MSCs, and
researched cell proliferation and survival under these
stressed conditions. Our findings indicated that AD-MSCs
cultured under 1.0% O2 showed enhanced proliferation com-
pared with those cells in 20.5% O2, while the proliferation
capacity of BM-MSCs decreased under 1.0% O2 compared
with 20.5% O2.
Reactive oxygen species (ROS) are produced by damaged
cells that cause oxidative stress and tissue damage during
SCI. Hydrogen peroxide (H2O2), one of the ROS, produce
hydroxyl radicals that cause tissue damage either through
direct oxidation or by triggering apoptotic signaling path-
ways54. We previously reported that transplanted MSCs die
by apoptosis10. Here, AD-MSCs had significantly greater
viability than BM-MSCs after 24 hours of exposure to high
H2O2 concentrations or serum-free conditions, indicating
that AD-MSCs are more resistant than BM-MSCs to cyto-
toxic conditions. Moreover, to compare survival rates of
AD-MSCs and BM-MSCs after transplantation, we used a
severe contusion model in mice. In this experiment, we
observed a greater survival rate of transplanted AD-MSCs
compared with BM-MSCs; these cells exhibited cell protru-
sions, which is indicative of a stromal morphology. Further-
more, the transplanted AD-MSCs expressed Akt and ERK1/
2 more strongly than transplanted BM-MSCs. Akt and
ERK1/2 are key factors that regulate cell survival and the
activation of these pathways promotes cell survival and inhi-
bits apoptosis4,55. Our findings support those of Ertaş et al.
who reported that AD-MSCs are more resistant than BM-
MSCs to low oxygen levels and serum deprivation56 and
suggested that Akt and ERK1/2 play important roles in this
protective effect. Our findings also suggest that the stronger
tolerance of AD-MSCs to cytotoxic stress-induced cell death
is important in their improved survival rates after
transplantation.
AD-MSCs, as the alternative cell source for SCI treat-
ment, may have different characteristics and mechanisms
of treatment effect compared with BM-MSCs. We examined
the angiogenic effects of AD-MSCs because we found evi-
dence of increased mRNA expression for angiogenic factors
in AD-MSCs compared with BM-MSCs in vitro, specifically
VEGF and CXCL12. Using immunofluorescence staining,
we showed that the prevalence of CD31-positive vascular
endothelial cells was significantly increased in the AD-
MSC transplanted group compared with either the BM-
MSC transplanted group or the control group at 7 days and
Fig. 6. The effects of AD-MSCs and BM-MSCs after transplantation on hind limb function. (A) BMS scores after MSC transplantation
following mild contusion SCI (60 kdyne contusion). Both MSC treatment groups showed significantly better motor function than the control
group. (B) BMS score after MSC transplantation following severe contusion SCI (80 kdyne contusion). There were no significant differences
between each of the groups. Data are show as mean+SD. n¼10 per groups, *p<0.05.
AD-MSC: adipose-derived mesenchymal stromal cell; BM-MSC: bone marrow-derived mesenchymal stromal cell; BMS: Basso Mouse Scale;
MSC: mesenchymal stromal cell; SCI: spinal cord injury; SD: standard deviation.
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14 days after treatment. Angiogenesis is regulated by numer-
ous cytokines, including VEGF, which is one of the most
important angiogenetic factors. VEGF binds to tyrosine
kinase receptors and stimulates angiogenesis57. In addition
to angiogenesis, VEGF as well as CXCL12 can also stimu-
late the development, protection and proliferation of neu-
rons58. Our findings also showed that PKCg-positive
corticospinal tract axonal staining was increased in the
AD-MSC transplanted group compared with the BM-MSC
group at 4 weeks after treatment.
The main purpose of MSC transplantation for SCI treat-
ment is functional improvement. The result showed both
AD-MSC and BM-MSC transplantation significantly
improve motor function compared with the control group
in a moderate contusion (60 kdyne) model. However, no
statistically significant differences were detected between
either treatment groups or the control group in a severe con-
tusion model (80 kdyne). The results suggest that there may
be a limitation to evaluating subtle changes in locomotor
movements using this rodent model and that there is a need
to further optimize the efficacy of MSC transplants.
Conclusion
In this study, we demonstrated that AD-MSCs have higher
tolerance to hypoxia, serum-free conditions and oxidative
stress compared with BM-MSCs in vitro. Moreover, AD-
MSCs showed higher survival rates than BM-MSCs when
transplanted into sites of severe SCI in vivo. AD-MSCs
synthesized trophic factors and cytokines/chemokines that
relate to neuronal survival, axonal regeneration, vasculariza-
tion, and increased cell survival. Increased prevalence of
CD31-positive vascular endothelium and PKC-positive cor-
ticospinal tract axons indicated increased neuroprotection
and healing in the AD-MSC transplanted mice compared
with BM-MSC transplanted mice, with functional improve-
ment after transplants of either MSC type in moderate con-
tusion SCI. Hence, our findings suggest AD-MSCs are a
particularly attractive cell therapeutic option for severe SCI
due to their enhanced stress resistance and secreted factor
profile.
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